Instrumental and Laboratory Changes in Post-Myocardial Infarction Prognosis: A Cross-Sectional Analysis

Basheer Abdullah Marzoog; Natalia Igorevna Bloshkina; Vera Sergeevna Gromova; Irina Andreevna Bakarova; Natalia Rudolfovna Chemekova; Elena Ivanovna Gorshinina

doi:10.1101/2023.02.25.23286453

Abstract

Background Cardiovascular events continue to be a leading cause of death worldwide.

Aims To evaluate the early laboratory and instrumental changes in a systematic manner in patients who experienced a recent myocardial infarction (MI).

Objectives To study patients with myocardial infarction occurring within 30 days prior to hospitalization in a rehabilitation hospital.

Materials and methods A large-scale retrospective cohort sectional study was conducted from 2014 to 2019, using data collected from Mordovia Rehabilitation Hospital. The study included 154 patients, with analysis of 76 parameters for each patient. Statistical analysis was performed using the Statistica program, employing t-tests, Pearson’s correlation coefficient, and ROC tests.

Results The sample consisted of 154 patients with a history of recent myocardial infarction. Of the total, 51 (33.11%) were female and 103 (66.88%) were male. Among the patients, 42 (27.27%) had chronic heart failure (CHF), while 101 (65.58%) did not, and 11 (7.142%) had missing data. Diabetes mellitus (DM) was observed in 28 (18.18%), with 118 (76.62%) without DM. Hypertension was present in 118 (76.62%), while 28 (18.18%) did not have hypertension. Chronic kidney disease (CKD) was seen in 11 (7.14%), with 131 (85.064%) not having CKD. Chronic obstructive pulmonary disease (COPD) was present in 14 (9.09%), while 132 (85.71%) did not have COPD. Post-myocardial infarction (MI) CHF was observed in 108 (70.13%), with 42 (27.27%) not having CHF. Post-MI arrhythmia was seen in 50 (32.47%) patients, while 99 (64.28%) did not have arrhythmia. Early post-MI complications, such as aneurysm, were present in 12 (7.79%), with 138 (89.61%) not having aneurysm. Dressler syndrome (pericarditis) was seen in 4 (2.59%) patients, pneumonitis in 1 (0.64%), and pleuritis was not observed.

Conclusions Systemic manifestations of myocardial infarction include kidney function impairment or the development of new kidney disease. These changes involve an increase in aorta basement diameter, right ventricle enlargement, decrease in serum red blood cell levels, serum potassium and calcium levels, and an increase in serum myoglobin. Elevated myoglobin levels are associated with the development of chronic heart failure. Higher creatinine levels and/or LDH are linked to the occurrence of arrhythmia. Hypertension is the predominant comorbid condition in MI patients, and arrhythmia is the most commonly reported post-MI complication.

Other findings Females are more susceptible to post-MI urinary tract infections.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The work of Basheer Abdullah Marzoog was financed by the Ministry of Science and Higher Education of the Russian Federation within the framework of state support for the creation and development of World-Class Research Center Digital biodesign and personalized healthcare № 075-15-2022-304.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study approved by the National Research Mordovia State University6 Russia, from Ethics Committee Requirement N8/2 from 30.06.2022.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes